Palatin Technologies is expected to report a fiscal fourth-quarter loss of $1.20 per share on revenue of approximately $1.25 million, as the stock trades at $7.77 against a high-conviction $53.50 average analyst price target. Investors are primarily focused on the company’s clinical pipeline updates, specifically the initiation of Phase 2 studies for its MC4R-based obesity program, PL7737.
Following the sale of Vyleesi, the company has transitioned to a clinical-stage focus, making updates on cash runway and R&D efficiency critical to maintaining its operations through mid-2027. Management commentary regarding potential sub-licensing or partnership deals for PL9643 in dry eye disease remains the primary catalyst for valuation recovery.